AVP and cystic kidney disease: Pharmacological receptor antagonists of AVP consistently reduce renal cyst growth and renal function decline in preclinical models and humans, but off-target effects (massive, rapid-onset and persistent aquaresis and increased risk for liver function derangement) are barriers for universal application in all patients with PKD [3, 27].